Biotech futures success mostly depends on the U.S. Food and Drug Administration’s decree, as well as on the clinical tests’ results. That’s why they are considered as one of the most changeable fortunes. One day they reach the top of the charts, and other days they hit bottom – or vice versa. Nevertheless, some companies seemed to overcome many difficulties this year and are now preparing to surge forward in the market.
Theravance Biopharma, Revance Therapeutics, and Immunomedics Stocks Rise
Theravance Biopharma works in different directions, exercising therapies in various areas. Their primary focus is on respiratory, cardiovascular, inflammatory, gastrointestinal, infectious, and immunology diseases. Despite their numerous efforts, their stock performance wasn’t ideal before now. But the FDA gave the green light to its new drug at the end of 2018. Yupelri is a treatment for the chronic obstructive pulmonary disease (COPD). Thirty-eight countries approved the company’s COPD treatment. In 2017, they gained a 31% market share. The experts predict even more growth in the future.
Revance Therapeutics is also reaching new highs. This biotech filed a Biologics License Application (BLA) for DAXI. It’s a long-lasting formulation of a neurotoxin treatment to cure frown lines. Therapeutics also signed a licensing deal with the Swiss company, Teoxane Laboratories. Due to the agreement, it gets the exclusive U.S. rights to its platform of hyaluronic-acid dermal fillers. According to Needham’s analyst, Serge Belanger, RVNC’s product line can get a significant portion from the $5 billion neuromodulator market. Experts predict that Revance Therapeutics can gain 42% over the next year.
Immunomedic’s main field is cancer treatment. It mostly manufactures monoclonal antibody-based products. In 2019, they tried to launch their new product, which is used as the final stage cure for metastatic triple-negative breast cancer. But the FDA issued concerns about “chemistry, manufacturing, and control” in the place where the company raised the drug plant. Immunomedics solved its problems and refiled the FDA’s application. Thus, experts feel confident that IMMU’s futures price will increase. It already rose from $26 to $31.